$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

$acur Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000114420415027285 Filed on May 04, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$5.357M	$42.00K
YoY Change	12654.76%	950.0%
Cost Of Revenue	$255.0K	$300.0K
YoY Change	-15.0%
Gross Profit	$5.102M	-$258.0K
YoY Change	-2077.52%
Gross Profit Margin	95.24%	-614.29%
Selling, General & Admin	$2.297M	$2.259M
YoY Change	1.68%	1.67%
% of Gross Profit	45.02%
Research & Development	$964.0K	$1.438M
YoY Change	-32.96%	-29.02%
% of Gross Profit	18.89%
Depreciation & Amortization	$30.00K	$30.00K
YoY Change	0.0%	0.0%
% of Gross Profit	0.59%
Operating Expenses	$3.261M	$3.868M
YoY Change	-15.69%	-8.95%
Operating Profit	$1.512M	-$3.826M
YoY Change	-139.52%	-9.85%
Interest Expense	$308.0K	$301.0K
YoY Change	2.33%
% of Operating Profit	20.37%
Other Income/Expense, Net	-$273.0K	-$262.0K
YoY Change	4.2%	-1107.69%
Pretax Income	$1.239M	-$4.088M
YoY Change	-130.31%	-3.08%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$1.239M	-$4.088M
YoY Change	-130.31%	-3.08%
Net Earnings / Revenue	23.13%	-9733.33%
Basic Earnings Per Share	$0.13	-$0.40
Diluted Earnings Per Share	$0.13	-$0.40
COMMON SHARES
Basic Shares Outstanding	9.793M shares	48.84M shares
Diluted Shares Outstanding	49.35M shares	48.84M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.21M	$22.49M
YoY Change	-36.81%	-4.1%
Cash & Equivalents	$3.821M	$8.866M
Short-Term Investments	$10.39M	$13.62M
Other Short-Term Assets	$310.0K	$910.0K
YoY Change	-65.93%	225.0%
Inventory	$280.0K	$100.0K
Prepaid Expenses
Receivables	$90.00K	$110.0K
Other Receivables	$60.00K	$100.0K
Total Short-Term Assets	$14.96M	$23.69M
YoY Change	-36.86%	-2.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$970.0K	$947.0K
YoY Change	2.43%	-7.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.0K	$220.0K
YoY Change	-31.82%	2100.0%
Total Long-Term Assets	$2.910M	$1.168M
YoY Change	149.14%	13.4%
TOTAL ASSETS
Total Short-Term Assets	$14.96M	$23.69M
Total Long-Term Assets	$2.910M	$1.168M
Total Assets	$17.87M	$24.86M
YoY Change	-28.12%	-1.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.0K	$493.0K
YoY Change	-67.55%	-63.48%
Accrued Expenses	$1.060M	$854.0K
YoY Change	24.12%	9.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.370M
YoY Change
Total Short-Term Liabilities	$3.760M	$1.642M
YoY Change	128.99%	-24.68%
LONG-TERM LIABILITIES
Long-Term Debt	$7.350M	$9.630M
YoY Change	-23.68%
Other Long-Term Liabilities	$240.0K	$50.00K
YoY Change	380.0%	400.0%
Total Long-Term Liabilities	$7.590M	$9.680M
YoY Change	-21.59%	96700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.760M	$1.642M
Total Long-Term Liabilities	$7.590M	$9.680M
Total Liabilities	$11.35M	$11.32M
YoY Change	0.28%	419.17%
SHAREHOLDERS EQUITY
Retained Earnings		-$353.2M
YoY Change
Common Stock		$366.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.520M	$13.54M
YoY Change
Total Liabilities & Shareholders Equity	$17.87M	$24.86M
YoY Change	-28.12%	-1.54%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	$1.239M	-$4.088M
YoY Change	-130.31%	-3.08%
Depreciation, Depletion And Amortization	$30.00K	$30.00K
YoY Change	0.0%	0.0%
Cash From Operating Activities	$2.170M	-$2.980M
YoY Change	-172.82%	-10.32%
INVESTING ACTIVITIES
Capital Expenditures	$46.00K	$34.00K
YoY Change	35.29%
Acquisitions
YoY Change
Other Investing Activities	$930.0K	$60.00K
YoY Change	1450.0%	200.0%
Cash From Investing Activities	$880.0K	$26.00K
YoY Change	3284.62%	23.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$520.0K
YoY Change	-100.0%	-27.17%
NET CHANGE
Cash From Operating Activities	2.170M	-$2.980M
Cash From Investing Activities	880.0K	$26.00K
Cash From Financing Activities	0.000	-$520.0K
Net Change In Cash	3.050M	-$3.474M
YoY Change	-187.8%	-13.5%
FREE CASH FLOW
Cash From Operating Activities	$2.170M	-$2.980M
Capital Expenditures	$46.00K	$34.00K
Free Cash Flow	$2.124M	-$3.014M
YoY Change	-170.47%	-9.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	298000	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.595
CY2015Q1	acur	Debt Instrument Cash Maintenance DebtInstrumentCashMaintenance	2500000	USD
CY2015Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	5000000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7900000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13000000	USD
CY2015Q1	acur	Restricted Stock Units Sale Price RestrictedStockUnitsSalePrice	0.01
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	51500000	USD
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	151400000	USD
CY2014Q1	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	76000	USD
CY2015Q1	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	41000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-89000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-18000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-3000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30000	USD
CY2014Q1	acur	Provision To Reduce Inventory To Net Realizable Value ProvisionToReduceInventoryToNetRealizableValue	133000	USD
CY2015Q1	acur	Provision To Reduce Inventory To Net Realizable Value ProvisionToReduceInventoryToNetRealizableValue	260000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	198000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	160000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	46000	USD
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2900000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	48000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2167000	USD
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1110000	USD
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1170000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	925000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	26000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	879000	USD
CY2015Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	51000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1000	USD
CY2015Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1000	USD
CY2014Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	529000	USD
CY2015Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-520000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-24000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	238000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3474000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	89000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3047000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12340000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8866000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	209000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-159000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	209000	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q1	acur	Common Stock Withheld Shares CommonStockWithheldShares		shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	298000	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.504
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.595
CY2014Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-214000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	219000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-56000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	313000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	419000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-353000	USD
CY2014Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	46000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2980000	USD
CY2015Q1	acur	Sales Returns Liability SalesReturnsLiability	153000	USD
CY2015Q1	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	22000	USD
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	ACURA PHARMACEUTICALS, INC
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000786947
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Trading Symbol TradingSymbol	ACUR
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49216817	shares
CY2014Q1	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	0	USD
CY2015Q1	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	255000	USD
CY2015Q1	acur	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	0	USD
CY2014Q4	acur	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	0	USD
CY2015Q1	acur	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	0	USD
CY2014Q4	acur	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	0	USD
CY2014Q1	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	198000	USD
CY2015Q1	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	160000	USD
CY2015Q1	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	153000	USD
CY2014Q4	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	0	USD
CY2015Q1	acur	Inventory Reserve For Raw Materials InventoryReserveForRawMaterials	260000	USD
CY2014Q4	acur	Inventory Reserve For Raw Materials InventoryReserveForRawMaterials	0	USD
CY2015Q1	acur	Additions To Debt Instrument Unamortized Discount AdditionsToDebtInstrumentUnamortizedDiscount	33000	USD
CY2015Q1	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	314000	USD
CY2014Q1	acur	Provision For Sales Returns ProvisionForSalesReturns	0	USD
CY2015Q1	acur	Provision For Sales Returns ProvisionForSalesReturns	153000	USD
CY2014Q1	acur	Inventory Reserve For Finished Goods InventoryReserveForFinishedGoods	133000	USD
CY2015Q1	acur	Marketing And Promotion MarketingAndPromotion	251000	USD
CY2014Q4	acur	Marketing And Promotion MarketingAndPromotion	61000	USD
CY2015Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	260000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	94000	USD
CY2015Q1	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	241000	USD
CY2014Q4	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	83000	USD
CY2015Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	17000	USD
CY2015Q1	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	17000	USD
CY2014Q4	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	13000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	33000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2015Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	0	USD
CY2015Q1	acur	Debt Instrument Classification Amount DebtInstrumentClassificationAmount	0	USD
CY2015Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	254000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	260000	USD
CY2014Q1	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	30000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1793000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1845000	USD
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	7961000	USD
CY2015Q1	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	241000	USD
CY2014Q4	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	190000	USD
CY2015Q1	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	31000	USD
CY2014Q1	us-gaap	Debt Issuance Costs DebtIssuanceCosts	17000	USD
CY2015Q1	us-gaap	Debt Issuance Costs DebtIssuanceCosts	17000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1758000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2522000	USD
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48848000	shares
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5000	USD
CY2015Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	86000	USD
CY2014Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	69000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	207000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	155000	USD
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	281000	USD
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48947000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48848000	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48947000	shares
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-4088000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	1239000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48842000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48947000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	0	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	18000	shares
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2014Q1	acur	Incremental Common Shares Attributable To Restricted Stock IncrementalCommonSharesAttributableToRestrictedStock	0	shares
CY2015Q1	acur	Incremental Common Shares Attributable To Restricted Stock IncrementalCommonSharesAttributableToRestrictedStock	170000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	167000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	63000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48842000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49347000	shares
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5861000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3580000	shares
CY2015Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	260000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	39000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	357000	USD
CY2014Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2015Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	5000000	USD
CY2014Q1	us-gaap	Revenues Revenues	42000	USD
CY2015Q1	us-gaap	Revenues Revenues	5357000	USD
CY2014Q1	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	38000	USD
CY2014Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	44000	USD
CY2015Q1	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	324000	USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	133000	USD
CY2015Q1	us-gaap	Inventory Write Down InventoryWriteDown	260000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1438000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	964000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2259000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2297000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	3868000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	3845000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3826000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1512000	USD
CY2015Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	35000	USD
CY2014Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-5000	USD
CY2015Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	301000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	308000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-262000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-273000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4088000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1239000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	29000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	31000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	29000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	31000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4059000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1270000	USD
CY2015Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	2800000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3500000	USD
CY2015Q1	acur	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	2600000	USD
CY2014Q4	acur	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	2800000	USD
CY2015Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10400000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11300000	USD
CY2015Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	10400000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11300000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2015Q1	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2015Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2014	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	13000	USD
CY2014Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	260000	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	282000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44000	USD
CY2015Q1	us-gaap	Inventory Gross InventoryGross	542000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	304000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	220000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	255000	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	195000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	253000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	120000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	49000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2741000	USD
CY2015Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2979000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2015Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0835	pure
CY2015Q1	acur	Debt Default Long Term Debt Percentage DebtDefaultLongTermDebtPercentage	0.1335	pure
CY2015Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
CY2015Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	50000	USD
CY2015Q1	acur	Debt Consulting Placement Fee DebtConsultingPlacementFee	100000	USD
CY2015Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	231000	USD
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	400000	USD

Files In Submission

Name	View Source	Status
0001144204-15-027285-index-headers.html	Edgar Link	pending
0001144204-15-027285-index.html	Edgar Link	pending
0001144204-15-027285.txt	Edgar Link	pending
0001144204-15-027285-xbrl.zip	Edgar Link	pending
acur-20150331.xml	Edgar Link	completed
acur-20150331.xsd	Edgar Link	pending
acur-20150331_cal.xml	Edgar Link	unprocessable
acur-20150331_def.xml	Edgar Link	unprocessable
acur-20150331_lab.xml	Edgar Link	unprocessable
acur-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v407835_10q.htm	Edgar Link	pending
v407835_ex31-1.htm	Edgar Link	pending
v407835_ex31-2.htm	Edgar Link	pending
v407835_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

2015 Q1 Form 10-Q Financial Statement

#000114420415027285 Filed on May 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR ACURA PHARMACEUTICALS, INC Stock $acur

2015 Q1 Form 10-Q Financial Statement

#000114420415027285 Filed on May 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur